Imidazole, given intraperitoneally to rabbits, inhibited the prostaglandin E1-induced (PGE1) elevation of intraocular pressure. The maximum imidaz-le effect occurred at three to six hours after intraperitoneal infection. The prostaglandin E1-induced aqueous humor protein elevation was reduced markedly in the imidazole-pretreated rabbits. Intravenous administration of imidazole also was effectiv...

15(S)-15-methyl-prostaglandin E1 and prostaglandin I2 rapidly and reversibly inhibit formyl-methionyl-leucyl-phenylalanine induced superoxide production by human neutrophils. In contrast, 15(S)-15-methyl-prostaglandin E1 and prostaglandin I2 did not alter the rate or the total amount of superoxide production by human neutrophils stimulated with either phorbol myristate acetate or arachidonic ac...

Using high density and low density lipoproteins (HDL and LDL) labeled with fluorescent analogues of phosphatidylcholine or sphingomyelin it was found that low amounts (10(-12) M) of prostaglandins E1 and F2 alpha induced different structural rearrangements of the lipoprotein surface, whereas prostaglandins E2 and F1 alpha had no effect. The effects of prostaglandin E1 on HDL were largely parall...

We previously showed the suppression of delayed-type hypersensitivity produced by live BCG-induced, plastic-adhering cells. The present study was undertaken to determine whether prostaglandin was one of the pharmacological mediators involved in this suppression. A high level of prostaglandin E1 was detected in the culture supernatant fluid of the live BCG-induced, adherent cells. Moreover, pros...

BACKGROUND Prostaglandin E1 is a potent vasodilator with anti-inflammatory and antiplatelet effects. We tested the hypothesis that prostaglandin E1 attenuates or prevents platelet aggregation-associated cyclic flow variations (CFVs) in severely stenosed and endothelium-injured coronary arteries. METHODS AND RESULTS We induced CFVs in 21 dogs by placing an external constrictor around the left ...

The effects of prostaglandin E1 on pulmonary circulation and left ventricular performance have been studied in 20 patients with mitral valve disease and pulmonary hypertension. Prostaglandin E1 was administered intravenously over a period of 30 minutes. The dose used was 0.01 microgram/kg per min during the first 15 minutes and 0.02 microgram/kg per min subsequently. The first dose led only to ...

The effects of infusions of prostaglandin E1 (PGE1) on platelet deposition at atherosclerotic sites in vivo in man have been examined. Thirteen patients with atherosclerotic vascular disease received intravenous PGE1 25 mg/kg/min for 6 hours daily for 5 days. Prostaglandin E1 had no effect on platelet uptake at atherosclerotic sites but prolonged platelet half-life significantly (P less than 0....

The formation of thrombi in vivo includes the activation of both platelets and the coagulation cascade. Conventional thrombolytic therapy is primarily directed toward the dissolution of fibrin. To evaluate the possibility that platelet activity impairs the lysis of thrombi, we studied the effects of aspirin and platelet-deaggregating prostaglandin E1 on thrombolysis with urokinase. Combined pla...